Micrograph News and Research

RSS

Research sheds light on specific protein interaction that could provide new treatment strategy to combat Cholera

Bacterial infectious diseases are still a huge contributor to global disease burden and with antibiotic resistance on the rise worldwide there is an urgent need for novel treatment strategies against bacteria.

14 Oct 2022

Clinical trial to evaluate antiviral drug for monkeypox begins in the Democratic Republic of the Congo

A clinical trial to evaluate the antiviral drug tecovirimat, also known as TPOXX, in adults and children with monkeypox has begun in the Democratic Republic of the Congo (DRC).

12 Oct 2022

Clinical trial to test the safety, efficacy of bacteriophages for treating P. aeruginosa infections in CF patients

Cystic fibrosis (CF) is an inherited disorder that causes severe damage to the lungs and other organs in the body.

11 Oct 2022

Impaired immune responses not responsible for COVID-19 rebound, findings suggest

Findings from a small study of eight patients published in Clinical Infectious Diseases suggest that COVID-19 rebound is likely not caused by impaired immune responses.

6 Oct 2022

UW Medicine researchers seek participants for Phase 3 clinical trial of a drug to treat monkeypox

UW Medicine researchers are recruiting participants for a Phase 3 clinical trial of a drug to treat the monkeypox virus.

16 Sep 2022

New method evaluates how mutations to SARS-CoV-2 can affect antibody recognition in rapid antigen tests

A research team funded by the National Institutes of Health has shown that commercially available rapid antigen tests can detect past and present variants of concern and has identified potential mutations that may impact test performance in the future.

15 Sep 2022

Phase 3 clinical trial commences to evaluate antiviral for monkeypox

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States.

9 Sep 2022

NIH issues funding opportunities to support the development of new COVID-19 diagnostics

The National Institutes of Health has issued two new funding opportunities for diagnostic test manufacturers to develop the next generation of COVID-19 tests, with a major focus on accessibility.

8 Sep 2022

Clinical trial begins evaluating alternative strategies to administer the JYNNEOS monkeypox vaccine

A clinical trial evaluating alternative strategies for administering the JYNNEOS monkeypox vaccine to increase the number of available doses has begun enrolling adult volunteers.

8 Sep 2022

SARS-CoV-2 antigen levels associated with COVID-19 severity and other clinical outcomes

The amount of SARS-CoV-2 antigen measured in the blood of patients hospitalized with COVID-19 is associated with illness severity and other clinical outcomes, according to a new study published in the Annals of Internal Medicine.

29 Aug 2022

NIH experts discuss a published case series detailing the symptoms and outcomes of monkeypox

Lessons learned from the public health responses to the HIV and COVID-19 pandemics should help guide the response to the current outbreak of monkeypox, National Institutes of Health experts write in an editorial published today in the New England Journal of Medicine.

25 Aug 2022

Mitochondrial DNA mutations are associated with an increased risk of atherosclerosis

Mitochondria are organelles found within most cells, best known for generating the chemical energy required to power cellular functions.

4 Aug 2022

Innovative technology reveals new insights into cellular reservoirs of HIV

In a presentation today at AIDS 2022, the 24th International AIDS Conference in Montreal, scientists with the National Institute of Allergy and Infectious Diseases' (NIAID) Vaccine Research Center (VRC) and their collaborators described how their use of cutting-edge technology revealed new insights into cellular reservoirs of HIV and what those observations could mean for the next steps in HIV cure research. NIAID is part of the National Institutes of Health.

27 Jul 2022

Improving the immune defenses against blood cancer

For patients with lymphoma, multiple myeloma, or certain types of leukemia, treatment with chimeric antigen receptor T cells (CAR T cells) is sometimes the last chance of overcoming the cancer.

22 Jul 2022

COVID-19 vaccine-boosted neutralizing antibody levels decrease substantially within 3 months

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substantially within 3 months, according to new clinical trial data.

19 Jul 2022

Study describes biochemical pathway that leads to inflammation characteristic of autoimmune diseases

Mitochondria are self-contained organelles (they possess their own mini-chromosome and DNA) residing within cells and are charged with the job of generating the chemical energy needed to fuel functions essential to life and well-being.

13 Jul 2022

NIH launches clinical trial evaluating an experimental vaccine to prevent Nipah virus infection

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an investigational vaccine to prevent infection with Nipah virus.

11 Jul 2022

COVID-19 was third leading cause of death in the United States between March 2020 and October 2021

COVID-19 was the third leading cause of death in the United States between March 2020 and October 2021, according to an analysis of national death certificate data by researchers at the National Cancer Institute, part of the National Institutes of Health. The study appears July 5 in JAMA Internal Medicine.

5 Jul 2022

Research examines possibility of monkeypox transmission in domestic settings

In a recent article posted to the medRxiv* preprint server, researchers conducted environmental sampling for an imported monkeypox virus (MPXV) case in the United Kingdom (UK).

30 Jun 2022

Treating anal precancerous growths reduces risk of anal cancer by more than half in HIV patients

A large clinical trial of people living with HIV has found that treating anal precancerous growths known as high-grade squamous intraepithelial lesions, or HSIL, reduces the chance that anal cancer will develop by more than half.

15 Jun 2022